131 related articles for article (PubMed ID: 38461903)
21. IRF-1 mediated long non-coding RNA PVT1-214 promotes oxaliplatin resistance of colorectal cancer via miR-128 inhibition.
Tong D; Zou E; Bai L; Ma J; Guo N; Wang H; Jiang L
J BUON; 2020; 25(5):2205-2214. PubMed ID: 33277837
[TBL] [Abstract][Full Text] [Related]
22. Resveratrol elicits anti-colorectal cancer effect by activating miR-34c-KITLG in vitro and in vivo.
Yang S; Li W; Sun H; Wu B; Ji F; Sun T; Chang H; Shen P; Wang Y; Zhou D
BMC Cancer; 2015 Dec; 15():969. PubMed ID: 26674205
[TBL] [Abstract][Full Text] [Related]
23. Tumor-Associated Macrophages Promote Oxaliplatin Resistance
Lan H; Liu Y; Liu J; Wang X; Guan Z; Du J; Jin K
Mol Pharm; 2021 Mar; 18(3):1026-1037. PubMed ID: 33555197
[TBL] [Abstract][Full Text] [Related]
24. TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach.
Cheraghi-Shavi T; Jalal R; Minuchehr Z
PLoS One; 2023; 18(8):e0289535. PubMed ID: 37535601
[TBL] [Abstract][Full Text] [Related]
25. Wnt/β-catenin signalling activates IMPDH2-mediated purine metabolism to facilitate oxaliplatin resistance by inhibiting caspase-dependent apoptosis in colorectal cancer.
Huang Y; Chan S; Chen S; Liu X; Li M; Zheng L; Dong Z; Yang Z; Liu Z; Zhou D; Zhang X; Zhang B
J Transl Med; 2024 Feb; 22(1):133. PubMed ID: 38310229
[TBL] [Abstract][Full Text] [Related]
26. Role of Dicer in regulating oxaliplatin resistance of colon cancer cells.
Lai HH; Lin LJ; Hung LY; Chen PS
Biochem Biophys Res Commun; 2018 Nov; 506(1):87-93. PubMed ID: 30336979
[TBL] [Abstract][Full Text] [Related]
27. Transcription factor B-MYB activates lncRNA CCAT1 and upregulates SOCS3 to promote chemoresistance in colorectal cancer.
Liu F; Wang Y; Cao Y; Wu Z; Ma D; Cai J; Sha J; Chen Q
Chem Biol Interact; 2023 Apr; 374():110412. PubMed ID: 36812959
[TBL] [Abstract][Full Text] [Related]
28. Metformin increases the cytotoxicity of oxaliplatin in human DLD-1 colorectal cancer cells through down-regulating HMGB1 expression.
Huang WS; Lin CT; Chen CN; Chang SF; Chang HI; Lee KC
J Cell Biochem; 2018 Aug; 119(8):6943-6952. PubMed ID: 29737584
[TBL] [Abstract][Full Text] [Related]
29. Oxaliplatin derived monofunctional triazole-containing platinum(II) complex counteracts oxaliplatin-induced drug resistance in colorectal cancer.
Li Y; Sun Z; Cui Y; Zhang H; Zhang S; Wang X; Liu S; Gao Q
Bioorg Chem; 2021 Feb; 107():104636. PubMed ID: 33465670
[TBL] [Abstract][Full Text] [Related]
30. Analysis of
Sharad S; Sztupinszki ZM; Chen Y; Kuo C; Ravindranath L; Szallasi Z; Petrovics G; Sreenath TL; Dobi A; Rosner IL; Srinivasan A; Srivastava S; Cullen J; Li H
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31842254
[TBL] [Abstract][Full Text] [Related]
31.
Qiu D; Hu J; Hu J; Yu A; Othmane B; He T; Ding J; Cheng X; Ren W; Tan X; Yu Q; Chen J; Zu X
Front Immunol; 2021; 12():705086. PubMed ID: 34777336
[TBL] [Abstract][Full Text] [Related]
32. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.
Wang H; Li H; Zhang L; Yang D
Biomed Pharmacother; 2018 Oct; 106():1607-1615. PubMed ID: 30119236
[TBL] [Abstract][Full Text] [Related]
34. Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer.
Wang K; Liu L; Zhang T; Zhu YL; Qiu F; Wu XG; Wang XL; Hu FQ; Huang J
Int J Nanomedicine; 2011; 6():3207-18. PubMed ID: 22238509
[TBL] [Abstract][Full Text] [Related]
35. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
[TBL] [Abstract][Full Text] [Related]
36. miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy
Sun C; Wang FJ; Zhang HG; Xu XZ; Jia RC; Yao L; Qiao PF
World J Gastroenterol; 2017 Mar; 23(10):1816-1827. PubMed ID: 28348487
[TBL] [Abstract][Full Text] [Related]
37. Low-dose orlistat promotes the therapeutic effect of oxaliplatin in colorectal cancer.
Zhang Q; Zhou Y; Feng X; Gao Y; Huang C; Yao X
Biomed Pharmacother; 2022 Sep; 153():113426. PubMed ID: 36017794
[TBL] [Abstract][Full Text] [Related]
38. Circ_0082182 upregulates the NFIB level via sponging miR-326 to promote oxaliplatin resistance and malignant progression of colorectal cancer cells.
Wang Z; Liu J; Yang T; Wang Q; Liang R; Tang J
Mol Cell Biochem; 2023 May; 478(5):1045-1057. PubMed ID: 36219357
[TBL] [Abstract][Full Text] [Related]
39. Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer.
Hashemi M; Esbati N; Rashidi M; Gholami S; Raesi R; Bidoki SS; Goharrizi MASB; Motlagh YSM; Khorrami R; Tavakolpournegari A; Nabavi N; Zou R; Mohammadnahal L; Entezari M; Taheriazam A; Hushmandi K
Transl Oncol; 2024 Feb; 40():101846. PubMed ID: 38042134
[TBL] [Abstract][Full Text] [Related]
40. Involvement of Met receptor pathway in aggressive behavior of colorectal cancer cells induced by parathyroid hormone-related peptide.
Novoa Díaz MB; Carriere P; Gigola G; Zwenger AO; Calvo N; Gentili C
World J Gastroenterol; 2022 Jul; 28(26):3177-3200. PubMed ID: 36051345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
